Cerenis Therapeutics plans to expand its staff this fall after raising tens of millions of dollars in venture capital investment over the last year.
The pharmaceutical company raised $85 million in its third round of investment, including cash from its traditional investors and some new faces. "We have very attractive programs," says Jean-Louis Dasseux, president & CEO of
Cerenis Therapeutics. "We're doing very well and we continue to have a number of investors invest in our company."
Cerenis Therapeutics is creating the first synthetic HDL, the so-called good cholesterol. The idea is to create a new way to remove plaque from heart tissue. The firm is working on the second phase of the clinical trial and hopes to have the synthetic HDL on the market by 2015 or 2016.
The six-year-old company's 25 staff members are evenly divided between its headquarters in both Ann Arbor and France. Dasseux expects to expand the head count at both offices later this year, starting with the hiring of a chief medical officer in September.
"We're looking to hire a lot of people with a lot of experience and wisdom," Dasseux says.
Source: Jean-Louis Dasseux, president & CEO of Cerenis TherapeuticsWriter: Jon ZemkeRead more about Metro Detroit's growing entrepreneurial ecosystem at
SEMichiganStartup.com.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.